The size of the Global Kidney Cancer Diagnostics and Therapeutics Market was worth USD 3.47 billion in 2020. It is forecasted to be growing at a CAGR of 5.64% to reach USD 4.57 billion by 2025.
Though there has been considerable development in science and technology to tackle cancer, it continues to threaten lives worldwide. Kidney cancer is one of the frequent urologic tumors accounting for around 3% of all human cancers. The frequency rate of renal cell carcinoma has increased gradually in recent decades.
The primary factor which significantly boosting the growth of the global kidney cancer diagnostics and therapeutics market is the increasing adoption of advanced therapy techniques such as cytokine-based treatment. The growing economies of the various countries are helping the healthcare industry grow at a high pace, further contributing to the growth of the global kidney cancer diagnostics and therapeutics market. Increasing demand for novel and effective diagnostics and therapeutics is another major factor catalyzing the growth of the Global Kidney Cancer Diagnostics and Therapeutics Market. Also, increased investments from governments and private organizations for research and development to develop minimally invasive techniques and the emergence of effective therapy procedures such as nephrectomy boost the global kidney cancer diagnostics and therapeutics market.
The emergence of novel and innovative diagnostics and therapeutic procedures such as cytokine and nephrectomy boosts the growth opportunities for key market players in this market, promoting growth during the forecast period across the world. The increasing prevalence of the geriatric population and growing demand for extensive diagnostics tests leads to the development and adoption of novel therapy procedures, which is creating several growth opportunities or the stakeholders operating in the global kidney cancer diagnostics therapeutics market. An increasing number of research and development activities for kidney cancer diagnostics and the emergence of technically advanced tests are likely to expand growth opportunities for the key players functioning in the international marketplace.
High costs associated with branded cancer drugs are the major challenge limiting the growth of the worldwide market. The increasing adoption rate of generic drugs is another major challenge restricting the development of the global kidney cancer diagnostics and therapeutics market.
REPORT COVERAGE:
|
REPORT METRIC |
DETAILS |
|
Market Size Available |
2019 to 2025 |
|
Base Year |
2019 |
|
Forecast Period |
2020 to 2025 |
|
Segments Covered |
By Type, Tests and Region |
|
Various Analyses Covered |
Global, Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities |
|
Regions Covered |
North America, Europe, APAC, Latin America, Middle East & Africa |
|
Market Leaders Profiled |
GlaxoSmithKline, Bayer, Pfizer, Sanofi S.A., Hoffmann La Roche, Novartis and Abbott Laboratories |
This research report on the global kidney cancer diagnostics and therapeutics market has been segmented and sub-segmented based on the type, tests, and region.
Kidney Cancer Diagnostics and Therapeutics Market – By Type:
The type of Renal Cell Carcinoma (RCC) is expected to account for the highest share in the kidney cancer diagnostics and therapeutics market. It is a type of kidney cancer. The RCC owes to the disease's high frequency, the existence of diagnostic procedures, and treatment therapies. RCC is most commonly seen in children and makes up to 2% to 6% of childhood. RCC affects 70% of the patients, and RCC's occurrence rate is high in North America. Around 270,000 new cases are diagnosed yearly, and out of those, 116,000 deaths took place. Regular renal cell carcinoma has been increasing steadily over the last twenty years. The factors responsible for RCC are lifestyle changes, genomic changes, and advancements in technology. The advanced Renal Cell Carcinoma therapeutics in Japan have achieved steady growth owing to the balance between the approval of combinational therapies and lifestyle changes.
Kidney Cancer Diagnostics and Therapeutics Market – By Tests:
Based on the tests, the biopsy and CT scan segments lead the growth in the market, holding 50% of the share in the market. Recent advancements like biopsy procedures are expected to provide healthy demand for kidney cancer diagnostics. The kidney Ultrasound segment is anticipated to lead the market, followed by biopsy and CT scan. High investments in research and development of kidney cancer diagnostics, significantly to enhance the accuracy of early-stage diagnostic tests, are boosting the segment growth in the kidney cancer diagnostic and therapeutics market globally.
Kidney Cancer Diagnostics and Therapeutics Market – By Region:
North America accounted for the largest share in the global Kidney Cancer Diagnostics and Therapeutics market, followed by Asia-Pacific and Europe. The frequency of this disease was higher in developed countries than in developing nations due to lifestyle factors. However, the Asia-Pacific region is anticipated to increase at the highest CAGR during the forecast period due to factors such as the low expense of drug production and the mounting patient base suffering from these diseases.
NOTABLE COMPANIES IN THIS MARKET
Key companies dominating the Global Kidney Cancer Diagnostics and Therapeutics Market profiled in this Market are GlaxoSmithKline, Bayer, Pfizer, Sanofi S.A., Hoffmann La Roche, Novartis, and Abbott Laboratories.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Type
5.1.1 Transitional Cell Cancer
5.1.2 Renal cell carcinoma
5.1.3 Renal sarcoma
5.1.4 Other Cancers
5.2 By Tests
5.2.1 Biopsy
5.2.2 CT Scan
5.2.3 Cystoscopy
5.2.4 Intravenous pyelogram
5.2.5 Kidney Ultrasound
6. Geographical Analysis
6.1 North America
6.1.1 Introduction
6.1.2 United States
6.1.3 Canada
6.2 Europe
6.2.1 Introduction
6.2.2 U.K
6.2.3 Spain
6.2.4 Germany
6.2.5 Italy
6.2.6 France
6.3 Asia-Pacific
6.3.1 Introduction
6.3.2 China
6.3.3 India
6.3.4 Japan
6.3.5 South Korea
6.3.6 Australia
6.4 Latin America
6.4.1 Introduction
6.4.2 Brazil
6.4.3 Argentina
6.4.4 Mexico
6.4.5 Rest of Latin America
6.5 Middle East & Africa
6.5.1 Introduction
6.5.2 Middle-East
6.5.3 Africa
7. Pipeline Product Analysis
7.1 Overview
7.2 Pipeline Development Landscape
7.3 Molecular Targets in the Pipeline
7.4 Clinical Trials
7.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target
7.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target
7.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target.
8.Strategic Analysis
8.1 PESTLE analysis
8.1.1 Political
8.1.2 Economic
8.1.3 Social
8.1.4 Technological
8.1.5 Legal
8.1.6 Environmental
8.2 Porter’s Five analysis
8.2.1 Bargaining Power of Suppliers
8.2.2 Bargaining Power of Consumers
8.2.3 Threat of New Entrants
8.2.4 Threat of Substitute Products and Services
8.2.5 Competitive Rivalry within the Industry
9.Market Leaders' Analysis
9.1 GlaxoSmithKline
9.1.1 Overview
9.1.2 Product Analysis
9.1.3 Strategic Evaluation and Operations
9.1.4 Financial analysis
9.1.5 Legal issues
9.1.6 Recent Developments
9.1.7 SWOT analysis
9.1.8 Analyst View
9.2 Bayer
9.3 Pfizer
9.4 Sanofi S.A
9.5 Hoffmann La Roche
9.6 Novartis
9.7 Abbott Laboratories
10.Competitive Landscape
10.1 Market share analysis
10.2 Merger and Acquisition Analysis
10.3 Agreements, collaborations and Joint Ventures
10.4 New Product Launches
11.Expert Opinions
11.1 Market Outlook
11.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Feb 2020
Download Sample
Feb 2020
Download Sample
Feb 2020
Download Sample
Feb 2020
Download Sample
Feb 2020
Download Sample
